Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer L Crombie

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Blood|January 9, 2025
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyMax S Topp, Matthew Matasar, John N Allan, et al.
The Lancet. Haematology|April 3, 2022
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trialRajat Bannerji, Jon E Arnason, Ranjana H Advani, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2025
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving ChemoimmunotherapyP Connor Johnson, Jeremy S Abramson, Ann S LaCasce, et al.
Leukemia & Lymphoma|August 8, 2022
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantationEleanor Taranto, Robert Redd, Erin Jeter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Blood|September 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid A Qualls, Nicholas Lambert, Paolo F Caimi, et al.
Blood Advances|June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamabAllison M Bock, Lei Feng, Ayushi Chauhan, et al.
Hemasphere|November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposureMwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Blood Neoplasia|December 24, 2025
Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockadeReid W Merryman, Justin Kline, Robert A Redd, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Blood|January 9, 2025
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyMax S Topp, Matthew Matasar, John N Allan, et al.
The Lancet. Haematology|April 3, 2022
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trialRajat Bannerji, Jon E Arnason, Ranjana H Advani, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2025
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving ChemoimmunotherapyP Connor Johnson, Jeremy S Abramson, Ann S LaCasce, et al.
Leukemia & Lymphoma|August 8, 2022
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantationEleanor Taranto, Robert Redd, Erin Jeter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Blood|September 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid A Qualls, Nicholas Lambert, Paolo F Caimi, et al.
Blood Advances|June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamabAllison M Bock, Lei Feng, Ayushi Chauhan, et al.
Hemasphere|November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposureMwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Blood Neoplasia|December 24, 2025
Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockadeReid W Merryman, Justin Kline, Robert A Redd, et al.
Pageof 6